Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peripheral blast count at apheresis as a risk factor for survival following tisagenlecleucel in children and young adults

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKristen MillerANAndrew NicklawskyHPHolly Pacenta

Discussion

Loading...

Member takes

Overview

Observational analysis found higher disease burden affects relapse rates in young patients treated with CAR T cell therapy.

Key Points

  • High disease burden at infusion correlated with inferior event-free survival in children and young adults.
  • Presence of peripheral blasts was linked to higher relapse rates post-CAR T cell therapy in this cohort.
  • Multivariable analysis indicated that blast percentage does not increase the hazard of death during treatment.
  • Findings suggest peripheral blasts may influence survival outcomes, warranting further investigation into their significance.

Cite This Study

Miller et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d536https://doi.org/10.1182/blood-2025-7638
View Full Paper
Ask AI
Bookmark
Share